A significant interaction between baseline exercise capacity and treatment effect for peak VOâ‚‚ (p=0.036) suggests that including high-functioning patients, whose physiologic ceiling may limit ...
A newly published, post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, significantly improves peak oxygen consumption ...